Asgard Therapeutics Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 29

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $2.59M

  • Investors
  • 14

Asgard Therapeutics General Information

Description

Developer of cancer immunotherapeutic systems designed to provide direct cell reprogramming for cancer immunotherapy. The company builds reprogramming technologies to develop gene therapy products to set efficient and personalized immune responses in motion, enabling patients to acquire new forms of treatment for cancer resistant to conventional treatment methods.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Medicon Village
  • Scheelevägen 2
  • 223 81 Lund
  • Sweden
+46 070-487
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Corporate Office
  • Medicon Village
  • Scheelevägen 2
  • 223 81 Lund
  • Sweden
+46 070-487

Asgard Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Asgard Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
14. Grant 22-Jan-2025 $2.59M Completed Pre-Clinical Trials
13. Accelerator/Incubator Completed Pre-Clinical Trials
12. Later Stage VC (Series A) 14-Mar-2024 Completed Pre-Clinical Trials
11. Grant 06-Mar-2024 Completed Pre-Clinical Trials
10. Grant 14-Apr-2023 Completed Startup
9. Seed Round 21-Nov-2021 Completed Startup
8. Grant 25-Oct-2021 Completed Startup
7. Grant 15-Apr-2021 Completed Startup
6. Grant 06-Apr-2020 $110K Completed Startup
5. Grant 01-Dec-2019 $55.3K Completed Startup
To view Asgard Therapeutics’s complete valuation and funding history, request access »

Asgard Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
To view Asgard Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Asgard Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of cancer immunotherapeutic systems designed to provide direct cell reprogramming for cancer immunotherapy. Th
Biotechnology
Lund, Sweden
29 As of 2026

Malmo, Sweden
 

Lund, Sweden
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Asgard Therapeutics Competitors (2)

One of Asgard Therapeutics’s 2 competitors is Chosa Oncology, a Corporation company based in Malmo, Sweden.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Chosa Oncology Corporation Malmo, Sweden
Cellevate Venture Capital-Backed Lund, Sweden
You’re viewing 2 of 2 competitors. Get the full list »

Asgard Therapeutics Patents

Asgard Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026003069-A1 Constructs and vectors for reprogramming cells to cdc1 cells, compositions and methods thereof Pending 25-Jun-2024
WO-2026003071-A2 Novel transcription factor combinations for immune cell reprogramming and related methods Pending 25-Jun-2024
WO-2026003071-A3 Novel transcription factor combinations for immune cell reprogramming and related methods Pending 25-Jun-2024
WO-2026003067-A1 Transcription factors and reprogramming modulators for reprogramming cells to cdc1 cells, compositions and methods thereof Pending 25-Jun-2024
AU-2024392973-A1 Rna-based strategies for dendritic cell reprogramming and uses thereof Pending 05-Dec-2023 C12N5/0639
To view Asgard Therapeutics’s complete patent history, request access »

Asgard Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Asgard Therapeutics Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds
Johnson & Johnson JJDC Corporate Venture Capital Minority
RV Invest Corporate Venture Capital Minority
European Innovation Council Accelerator/Incubator
Boehringer Ingelheim Venture Fund Corporate Venture Capital Minority
Industrifonden Venture Capital Minority
You’re viewing 5 of 14 investors. Get the full list »

Asgard Therapeutics FAQs

  • When was Asgard Therapeutics founded?

    Asgard Therapeutics was founded in 2018.

  • Where is Asgard Therapeutics headquartered?

    Asgard Therapeutics is headquartered in Lund, Sweden.

  • What is the size of Asgard Therapeutics?

    Asgard Therapeutics has 29 total employees.

  • What industry is Asgard Therapeutics in?

    Asgard Therapeutics’s primary industry is Biotechnology.

  • Is Asgard Therapeutics a private or public company?

    Asgard Therapeutics is a Private company.

  • What is Asgard Therapeutics’s current revenue?

    The current revenue for Asgard Therapeutics is .

  • How much funding has Asgard Therapeutics raised over time?

    Asgard Therapeutics has raised $82.6M.

  • Who are Asgard Therapeutics’s investors?

    Johnson & Johnson JJDC, RV Invest, European Innovation Council, Boehringer Ingelheim Venture Fund, and Industrifonden are 5 of 14 investors who have invested in Asgard Therapeutics.

  • Who are Asgard Therapeutics’s competitors?

    Chosa Oncology and Cellevate are competitors of Asgard Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process